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Activating mutations within the epidermal growth factor receptor (EGFR) identify lung adenocarcinoma patients with improved
clinical responses to tyrosine kinase inhibitors gefitinib and erlotinib. By screening salivary gland carcinoma, two drug-sensitizing EGFR
exon 19 delE746-A750 mutations were identified in an adenocystic and in a mucoepidermoid carcinoma of the parotid gland.
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Recent studies (Lynch et al, 2004; Paez et al, 2004; Eberhard et al,
2005; Riely et al, 2006) have identified a subset of lung cancer
patients with rapid and durable clinical responses to epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e.
gefitinib, erlotinib) and found an underlying association between
activating mutations in the EGFR tyrosine kinase domain and
therapy response. Two mutations account for approximately 90%
of EGFR mutations reported to date in lung adenocarcinoma (Pan
et al, 2005). An in-frame deletion of 9–24 nucleotides in exon 19
centred around codons 746–750 makes up about 50% of
mutations. The second most common mutation is a point
mutation at nucleotide 2573 (CTGt oC GG) in exon 21 that results
in the substitution of leucine by arginine at codon 858 (L858R).
Organotypical salivary gland carcinomas (SGCs) have a
comparable embryonal tissue origin to lung adenocarcinoma.
Epidermal growth factor receptor has been shown to be over-
expressed in both salivary adenoid cystic carcinoma (ACC) and
non-ACC (Agulnik et al, 2007). We hypothesised that EGFR-
activating mutations in SGC might occur, making EGFR a potential
molecular target for therapy also in these rare tumours with poor
prognosis and limited response to traditional chemotherapies.
MATERIALS AND METHODS
Samples and DNA isolation
Formalin-fixed tumour samples were obtained from 25 patients
(16 males and 9 females with a median age at diagnosis of 61 years)
treated at the HELIOS Clinical Center Erfurt, Germany, with the
histopathological diagnosis of a SGC according to the WHO
classification (Barnes et al, 2005). The study cohort consisted of
ACC (n¼11), mucoepidermoid carcinoma (n¼6), epithelial–
myoepithelial carcinoma (n¼6) and acinic cell carcinoma (n¼2).
This study was conducted in accordance with the principles of the
Declaration of Helsinki, as adopted by the 29th World Medical
Assembly, Helsinki, Finland.
Heterozygous mutant control DNA was extracted from lung
cancer cell lines NCI-H-1650 and NCI-H-1975 (American Type
Culture Collection, LGC Promochem, Wesel, Germany), which
contain the exon 19 E746_A750 deletion and the exon 21 L 858R
point mutation, respectively.
DNA was isolated from microdissected tumour areas using the
QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany).
Exon 19 E746_A750del and exon 21 L 858R point mutation
detection assays
Mutation screening was performed by two allele-specific PCR
assays and discrimination of the allele-specific PCR fragments by
agarose gel electrophoresis.
For detecting the exon 19 deletion, a so-called Bi-PASA
assay was used with allele-specific primers, which can detect
both possible nucleotide deletions (c.2235_2249del15 and
c.2236_2250del15) that give rise to an E746_A750del protein
change. Exon 21L 858R was screened by allele-specific PCR (Dahse
et al, 2008).
Sequencing
The EGFR mutations were confirmed by genomic DNA sequencing
of the relevant regions of exon 19. PCR products were purified with
the MinElute PCR Purification Kit (Qiagen GmbH). Genomic
sequencing (MWG Biotech, Martinsried, Germany) was performed
using the appropriate downstream PCR primer.
RESULTS
DNA was isolated from microdissected areas of 25 SGCs (obtained
by biopsy or surgical resection) and screened for the both most
common EGFR-activating mutations.
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sThe mutant exon 21 2573G allele was not detectable.
We identified two exon 19 E746_A750 deletions. Genomic
sequencing confirmed both exon 19 deletions to be the variant
c.2235_2249del15 (Figure 1). Case 1 was a 54-year-old female
patient with a mucoepidermoid carcinoma of the left parotid gland
grade 2, case 2 was a 69-year-old male patient with an ACC of solid
type of the right parotid gland.
The exon 19 Bi-PASA assay included a PCR control fragment
that was always amplified indicating the integrity of the isolated
DNA from microdissected clinical tissue samples.
DISCUSSION
This is the first report of the detection of an EGFR hot-spot
mutation (known from lung cancer to be correlated to gefitinib/
erlotinib therapy sensitivity) in SGCs.
Approximately 10–30% of lung carcinoma contain EGFR
mutations (Yatabe and Mitsudomi, 2007). Retrospective studies
found that after treatment with gefitinib or erlotinib, lung cancer
patients with EGFR exon 19 deletions had a longer overall survival
when compared with patients with EGFR L858R (Jackman et al,
2006; Riely et al, 2006).
It is known that EGFR mutations in the tyrosine kinase
domain are seldom acquired in the cancers of other organs
(EGFR mutation database: http://www.cityofhope.org/cmdl/
egfr%5Fdb/).
We detected in 2 out of 25 SGC (8%/95% exact confidence limit:
1.4–27.5%) the recurrent delE746-A750 mutation known from
lung cancer.
Salivary gland carcinomas are treated mainly with surgery and
radiation, and response rates to conventional chemotherapy are
generally low. Given this, patients with SGC might profit from
trials of investigational new therapies. C-kit is overexpressed in a
wide percentage of SGCs, but clinical trials with single-agent
imatinib have been negative. ErbB1 and ErbB2 are also frequently
overexpressed in salivary gland cancers and this has provided the
rationale for clinical trials with trastuzumab, cetuximab, gefitinib
and lapatinib. Twenty-nine patients with incurable SGCs
were accrued in a phase II trial of gefitinib, an orally active
ErbB1-inhibitor. Gefitinib was associated with a 53% stable disease
rate (10/19) in ACC, which was maintained for 16 weeks in 26%
(5/19) of the patients in this cohort. Cetuximab (Erbitux, C225), a
human-murine chimeric monoclonal antibody to ErbB1, has
been tested in a phase II study in 30 patients with recurrent and/
or metastatic SGCs. Among 22 patients evaluable for response
after at least 3 months of treatment, 11 patients had stable
disease, 9 had progressive disease, while 2 patients
refused to continue after 1 month (Milano et al, 2007). In a
phase II study of lapatinib in EGFR and/or erbB2-expressing
SGCs, the antitumour effects appeared mainly cytostatic
(Agulnik et al, 2007).
In conclusion, the presence of EGFR-activating mutations
in SGCs might identify patients that would profit from
tyrosine kinase inhibitor therapies. On the other hand,
those patients with an EGFR-activating mutation would not benefit
from the competitive inhibition of EGF on its receptor. The
identification of EGFR-activating mutations is essential for the
selection of the EGFR-targeting therapy strategy (receptor-specific
antibody vs tyrosine kinase inhibitor). Because the growth factor
signal is generated in the mutated receptor itself, a prereceptor
blocking of the ligand has no specific effect. A maximal effect is
yielded by blocking the signalling pathways downstream of the
receptor.
Our finding of the presence of activating EGFR mutations in
SGCs should initiate further studies on other more rare kinase
domain mutations that are known to be associated with
drug sensitivity (G719A/C point mutation in exon 18 and L861Q
in exon 21).
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Figure 1 Epidermal growth factor receptor (EGFR) mutation screening
in malignant salivary gland tumours. (A) Exon 19 E746_A750 deletion Bi-
PASA assay. The Exon 19 deletion is detected by an allele-specific 134bp
fragment (arrow). It is seen in the positive control (NCI-H-1650, lane 2)
and was found in a mucoepidermoid carcinoma of the left parotid gland
(lane 5) and in an adenoid cystic carcinoma (ACC) of solid type of the right
parotid gland (lane 6). No deletions were detected in other malignant
tumours (lane 7: ACC; lanes 8 and 9: mucoepidermoid carcinoma; lane 10:
acinic cell carcinoma). Lane 1: molecular weight marker; lane 3: wild-type
DNA control, lane 4: no template PCR control (water). (B) Part of the
wild-type (wt) EGFR exon 2 genomic sequence. The 15bp deletion is
schematically depicted (mut). (C) Genomic sequencing of EGFR exon 2 in
both SGC tumour samples harbouring the deletion c.2235_2249del15. (D)
Exon 21 L858R allele-specific PCR assay. Left figure: the wild-type-specific
PCR fragment was detected in all tumour samples (lanes 5–10), in the
heterozygous positive control (NCI-H-1975, lane 2) and in the wild-type
DNA control (lane 3). Right figure: the mutant G 2573G allele is amplified
only in the positive control and was not found in the tumour samples.
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